6.09
전일 마감가:
$6.15
열려 있는:
$6.21
하루 거래량:
750.65K
Relative Volume:
0.57
시가총액:
$166.97M
수익:
$160.43M
순이익/손실:
$-227.64M
주가수익비율:
-0.0886
EPS:
-68.77
순현금흐름:
$-170.79M
1주 성능:
-10.83%
1개월 성능:
+27.41%
6개월 성능:
+59.01%
1년 성능:
+1.67%
아제너스 Stock (AGEN) Company Profile
명칭
Agenus Inc
전화
781-674-4410
주소
3 FORBES ROAD, LEXINGTON, MA
AGEN을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
![]()
AGEN
Agenus Inc
|
6.09 | 187.26M | 160.43M | -227.64M | -170.79M | -68.77 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
458.49 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
545.53 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
320.52 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
566.14 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
291.93 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
아제너스 Stock (AGEN) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2025-06-04 | 업그레이드 | H.C. Wainwright | Neutral → Buy |
2024-07-19 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
2024-07-18 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2024-07-18 | 다운그레이드 | William Blair | Outperform → Mkt Perform |
2023-06-06 | 개시 | Robert W. Baird | Outperform |
2023-02-28 | 재개 | H.C. Wainwright | Buy |
2022-09-28 | 개시 | SMBC Nikko | Outperform |
2021-12-16 | 개시 | H.C. Wainwright | Buy |
2019-11-19 | 재개 | B. Riley FBR | Buy |
2019-04-22 | 개시 | B. Riley FBR | Buy |
2016-10-28 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
2016-10-27 | 재확인 | Maxim Group | Buy |
2016-03-11 | 업그레이드 | Maxim Group | Hold → Buy |
2015-12-16 | 개시 | Jefferies | Buy |
2015-10-27 | 다운그레이드 | Maxim Group | Buy → Hold |
2015-07-27 | 재확인 | MLV & Co | Buy |
2015-06-11 | 개시 | Oppenheimer | Outperform |
2015-01-12 | 재확인 | Maxim Group | Buy |
2015-01-09 | 재확인 | MLV & Co | Buy |
2015-01-09 | 재확인 | Maxim Group | Buy |
2014-12-19 | 재확인 | Maxim Group | Buy |
2014-05-08 | 재확인 | Maxim Group | Buy |
2014-03-14 | 재확인 | MLV & Co | Buy |
2013-10-08 | 재확인 | Maxim Group | Buy |
2012-01-05 | 개시 | William Blair | Outperform |
2011-12-01 | 개시 | Global Hunter Securities | Buy |
모두보기
아제너스 주식(AGEN)의 최신 뉴스
Is Agenus Inc. a good long term investmentUnprecedented market success - Autocar Professional
Agenus Inc. Stock Analysis and ForecastMarket-beating performance - jammulinksnews.com
What analysts say about Agenus Inc. stockConsistently profitable trades - jammulinksnews.com
Colon cancer impacts far more than just the body – Agenus - Oncodaily
Agenus unit, MiNK surges after peer-reviewed data for lead drug - MSN
Zydus Lifesciences receives final approval from USFDA for Celecoxib Capsules - MarketScreener
AGEN Stock Outpaces Medical Sector Peers This Year - AInvest
Is Agenus (AGEN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Agenus (AGEN) Surges 19.3%: Is This an Indication of Further Gains? - Yahoo Finance
Public Companies Hold Majority of MiNK Therapeutics Stock After 815% Gain - AInvest
Agenus Responds to New Regulatory Environment at FDA - Oncodaily
Agenus Inc. shares surge 19.54% intraday after positive clinical data and strategic partnership. - AInvest
Zacks.com featured highlights Yext, Agenus and NCR Voyix - The Globe and Mail
Agenus stock maintains Buy rating at H.C. Wainwright after positive bot/bal data - Investing.com Canada
Investors Turn to Cancer Breakthroughs as Federal Funding Faces Deep Cuts - Baystreet.ca
Agenus stock maintains Buy rating at H.C. Wainwright after positive bot/bal data By Investing.com - Investing.com South Africa
Agenus Inc. shares fall 1.35% in after-hours trading after FDA questions efficacy data for BOT/BAL combination. - AInvest
Botensilimab and Balstilimab Achieves 21-Month Survival in mCRC and FDA Endorsement for Global Phase 3 Trial - Oncodaily
Agenus' BOT/BAL in MSS CRC: A Breakthrough with Accelerated Approval on the Horizon? - AInvest
Agenus reports 42% two-year survival in colorectal cancer trial - Investing.com
Agenus' BOT/BAL Combo Achieves 42% Two-Year Survival in Refractory MSS CRC, Advances Toward FDA Registration with Phase 3 Trial Design Alignment. - AInvest
42% Survival Rate: Agenus Cancer Drug Shows Breakthrough in Resistant Colorectal Cancer | AGEN Stock News - Stock Titan
Rockford Register Star: Local News, Politics & Sports in Rockford, IL - FinancialContent
Agenus Inc. shares surge 8.17% intraday after HC Wainwright & Co. analyst upgrades rating to strong buy. - AInvest
Baird Lifts Agenus (AGEN) PT to $6, Maintains Neutral Rating - MSN
Agenus Requests to Dismiss Class Action Filed by Investors - TradingView
Agenus Inc.(NasdaqCM: AGEN) dropped from Russell Small Cap Completeness Index - MarketScreener
Agenus Inc.(NasdaqCM: AGEN) dropped from Russell 2000 Growth Index - MarketScreener
Agenus Inc.(NasdaqCM: AGEN) dropped from Russell 2500 Index - MarketScreener
Agenus Holds Annual Stockholders Meeting on June 17 - TipRanks
# Agenus and Noetik partner to develop AI-powered cancer treatment biomarkers - Investing.com India
Agenus Inc. (AGEN) Surges After Zydus Agreement, Analysts Upbeat on Stock - MSN
Agenus Partners With Noetik to Advance Biomarker Discovery for Lead Cancer Immunotherapy Combo - MarketScreener
Agenus (AGEN) and Noetik Collaborate to Enhance Cancer Treatment - GuruFocus
Agenus, Noetik Enter Research Collaboration - Nasdaq
Agenus and Noetik Enter Collaboration to Develop AI-Enabled Predictive Biomarkers for BOT/BAL Using Foundation Models of Virtual Cell Biology | AGEN Stock News - GuruFocus
AI Breakthrough: Agenus and Noetik Join Forces to Revolutionize Cancer Patient Selection Using Virtual Cell Models - Stock Titan
10 Most Undervalued Stocks to Buy for Under $5 - Insider Monkey
Zydus Life To Buy Agenus' US Facilities For $75 Million For Entry In Biologics CDMO - MSN
Neoantigen Cancer Vaccines Industry Analysis Report 2025 with Tariff-Adjusted Forecasts and Analytics to 2030 - GlobeNewswire Inc.
Is Zydus’s Agenus Deal Opportunistic Or Strategic? - insights.citeline.com
Agenus Inc. Sued for Securities Law ViolationsContact Levi & Korsinsky Before November 5, 2024 to Discuss Your RightsAGEN - ACCESS Newswire
H.C. Wainwright Upgrades Agenus (AGEN) Stock to Buy - MSN
Agenus Announces Virtual Annual Shareholders Meeting - New Castle News
How to Join Agenus 2025 Virtual Shareholders Meeting: Complete Registration Guide - Stock Titan
Agenus climbs on deal with India’s Zydus for cancer therapy BOT/BAL - MSN
Agenus' 2025 Annual Meeting Highlights Pipeline Breakthroughs and Governance Gains, Bolstering Oncology Innovation Play - AInvest
Agenus Inc. (NASDAQ:AGEN) Receives Consensus Rating of “Hold” from Analysts - Defense World
Research Analysts Issue Forecasts for Agenus FY2027 Earnings - Defense World
HC Wainwright Forecasts Agenus’ Q3 Earnings (NASDAQ:AGEN) - Defense World
Zydus Lifesciences venture capital arm to acquire stake in Agenus for USD 16 million - Medical Dialogues
아제너스 (AGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):